In the company’s announcement, Frequency Therapeutics provides updates on data from its recent FX-322 Clinical Readouts, including new information from a Phase 1b study in presbycusis, and further clarifies acquired sensorineural hearing loss target populations and future study design. The company anticipates initiating a new FX-322 Phase 2 Study in H2 2021.